Switzerland· 67669001
Vocabria 30 mg, Filmtabletten
A cabotegravir product containing cabotegravirum, registered in Switzerland by ViiV Healthcare GmbH and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Cabotegravir is registered in 14 of 19 countries.
Countries holding a registration under ATC J05AJ04 (cabotegravir), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 9 of them publish a price we can compare per daily dose
Cabotegravir · ATC J05AJ04
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of cabotegravir costs, country by country.
Normalised to the WHO defined daily dose (30 mg), so markets compare like for like.
- Switzerland: $24.58 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Cabotegravir · price per daily dose (30 mg)
USD · FX 28 Sept 2026
- CH Switzerland$24.58
- FR France$20.75
The record
At a glance
Swissmedic (Switzerland)- Active substance
- cabotegravirum
- Manufacturer
- ViiV Healthcare GmbH
- Country
- Switzerland (CH)
- ATC code
- J05AJ04
- ATC class
- Cabotegravir
- Defined daily dose
- 30 mg, O
- Swissmedic category
- A
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin7680676690014Fl 30 StkCHF 611.45
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
13 interactions on record for cabotegravir.
Graded by severity as the source publishes them — 13 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Cabotegravir · interactions on record
13 records
- 13 moderate
Most severe, free to view
- Magnesium carbonateA02AA01moderate
- Magnesium oxideA02AA02moderate
- Magnesium hydroxideA02AA04moderate
- Kombinationen von AluminiumsalzenA02AB10moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Cabotegravir in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandApretudeViiV Healthcare BV
- CzechiaAPRETUDEViiV Healthcare BV, Amersfoort
- SpainAPRETUDE 30 MG COMPRIMIDOS RECUBIERTOS CON PELICULAViiv Healthcare B.V.
- FranceAPRETUDE 30 mg, comprimé pelliculéVIIV HEALTHCARE (PAYS-BAS)
- BelgiumApretude 30 mgViiV Healthcare
- NetherlandsApretude 30 mg filmomhulde tabletViiV Healthcare B.V.
- PolandApretudeViiV Healthcare BV
- SwedenApretude 30 mg Filmdragerad tablettViiV Healthcare BV
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Apretude, Vocabria
- Liechtenstein · Apretude, Vocabria
- Norway · Apretude, Vocabria
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/de6f8e56-5549-4200-9cd9-4d40bb69eca3 GET /v1/drugs/de6f8e56-5549-4200-9cd9-4d40bb69eca3?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "cabotegravirum 30 mg",
"valid_from": "2022-03-01",
"limitations": "[{\"description\":\"VOCABRIA Tabletten werden nur in Kombination mit Rilpivirin Tabletten zur kurzfristigen Behandlung einer HIV-1-Infektion bei Erwachsenen vergütet, die seit mindestens 6 Monaten vor Umstellung auf die Cabotegravir-Rilpivirin-Kombination unter einer stabilen antiretroviralen Therapie virologisch supprimiert (HIV-1 RNA <50 Kopien/ml) sind und keine bekannten oder vermuteten Resistenzen gegen sowie in der Vorgeschichte kein virologisches Versagen mit Wirkstoffen aus der NNRTI- oder INI-Klasse aufweisen.<br>\\n<br>\\nVOCABRIA Tabletten werden vergütet zur oralen Einleitungsbehandlung, um vor Therapiebeginn mit langwirksamen Cabotegravir-Injektionen die Verträglichkeit von Cabotegravir in Kombination mit Rilpivirin Tabletten zu testen oder als orale Überbrückungsbehandlung für Erwachsene, die geplante Cabotegravir-Injektionen versäumen werden.<br>\\n<br>\\n\",\"costApproval\":null,\"indication\":\"\",\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2025-12-01\"}]",
"galenic_form": "Filmtabl 30 mg",
"therapeutic_area": null,
"sl_inclusion_date": "2022-03-01",
"self_retention_pct": 10
}See everything about cabotegravir.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.